Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
GNAS NP_000507.1:p.Q125R	NCIT_C146954	[A change in the amino acid residue at position 125 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where glutamine has been replaced by arginine.]
GNAS NM_000516.5:c.478C>T	NCIT_C146955	[A nucleotide substitution at position 478 of the coding sequence of the GNAS gene where cytosine has been mutated to thymine.]
GNAS NP_000507.1:p.R160C	NCIT_C146956	[A change in the amino acid residue at position 160 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where arginine has been replaced by cysteine.]
GNAS NM_000516.5:c.602G>A	NCIT_C146957	[A nucleotide substitution at position 602 of the coding sequence of the GNAS gene where guanine has been mutated to adenine.]
GNAS NP_000507.1:p.R201H	NCIT_C146958	[A change in the amino acid residue at position 201 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where arginine has been replaced by histidine.]
Coughing at its Worst	NCIT_C107380	[A question about an individual's coughing at its worst.]
Sore Throat at its Worst	NCIT_C107381	[A question about an individual's sore throat at its worst.]
Difficulty Swallowing at its Worst	NCIT_C107382	[A question about an individual's difficulty swallowing at its worst.]
Pedicle TRAM Flap Procedure	NCIT_C107383	[A type of breast reconstruction in which a section of skin, muscle, fat, and blood vessels from the abdomen is separated from surrounding tissue while retaining its blood supply, and tunneled under the skin to form a new breast mound.]
TRAM Flap Procedure	NCIT_C160624	[A grafting procedure where a piece of tissue, including skin, fat, and all or part of the underlying transverse rectus abdominis muscle are used for breast reconstruction.]
Milademetan Tosylate	NCIT_C107384	[The tosylate form of milademetan, an orally available MDM2 (murine double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, milademetan binds to, and prevents the binding of MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This results in the restoration of p53 signaling and leads to the p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it has been implicated in cancer cell proliferation and survival.]
MDM2 Inhibitor	NCIT_C162996	[Any agent that binds to mouse double minute 2 (human double minute 2 homolog; MDM2; HDM2) and prevents the interaction with the tumor suppressor protein p53, with potential antineoplastic activity.]
Ultra Low Temperature Freezer	NCIT_C107385	[A type of freezer that can maintain temperatures between -80 and -86 degrees C.]
Freezer	NCIT_C84327	[A refrigerated cabinet or room for preserving materials at or below 32F (0C).]
CDKN2A NP_000068.1:p.A148T	NCIT_C146950	[A change in the amino acid residue at position 148 in the cyclin-dependent kinase inhibitor 2 protein where alanine has been replaced by threonine.]
CDKN2A Protein Variant	NCIT_C146926	[A variation in the amino acid sequence for a protein encoded by the CDKN2A gene.]
Cyclin-Dependent Kinase Inhibitor 2A	NCIT_C17786	[Cyclin-dependent kinase inhibitor 2A (156 aa, ~17 kDa) is encoded by the human CDKN2A gene. This protein is involved in the inhibition of both cell proliferation and cell cycle progression.]
CDKN2A NM_000077.4:c.442G>A	NCIT_C146949	[A nucleotide substitution at position 442 of the coding sequence of the CDKN2A gene where guanine has been mutated to adenine.]
PI3K Inhibitor WX-037	NCIT_C107386	[A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor WX-037 specifically inhibits PI3K, which prevents the activation of the PI3K/protein kinase B-mediated signaling pathway. This may result in the inhibition of both tumor cell growth and survival in PI3K-overexpressing tumor cells. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.]
BP-Cx1-Platinum Complex BP-C1	NCIT_C107387	[A combination agent composed of the benzo-poly-carbonic-acid polymer BP-Cx1 chelated to platinum with potential antineoplastic activity. Upon intramuscular injection, the polymer moiety of BP-Cx1-Platinum Complex BP-C1 (BP-C1) alters the permeability of the cell membranes, which allows for increased penetration of platinum into tumor cells. In turn, platinum binds to nucleophilic groups such as GC-rich sites in DNA and induces intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition. In addition, the BP-Cx1 ligand is able to stimulate the innate immune system and upregulates a variety of cytokines including interferon, tumor necrosis factor-alpha (TNF-alpha), granulocyte macrophage-colony stimulating factor (GM-CSF), and various interleukins (ILs) such as IL-6 and IL-25. In comparison to cisplatin and other platinum-based compounds, treatment with BP-C1 allows for less platinum administration, which reduces platinum-associated systemic toxicity and side effects, and enhances the safety profile while maintaining or improving its efficacy.]